Gefitinib  (Synonyms: 吉非替尼; ZD1839)

Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor^[1][2].

IC50: 37 nM (Tyr1173 site, in NR6wtEGFR cells), 37 nM (Tyr992 site, in NR6wtEGFR cells)^[1].

Gefitinib (GMP) abolishes the effect of EGF-induced dedifferentiation of astrocytes into astrocyte precursor cells (APCs)^[2].
Gefitinib (3 μM) can produce a subgroup of EGFR-mutant NSCLC cell lines (Gefitinib-resistant cells) that undergo cellular reprogramming, such as HCC827 cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

446.90

C₂₂H₂₄ClFN₄O₃

184475-35-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54.  [Content Brief]

  [2]. Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28(1):50.  [Content Brief]

  [3]. Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2(3):e39.  [Content Brief]